Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
UTHR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$221.53 - $417.82
Previous CloseN/A
Volume58.00K
Average Volume (3M)360.50K
Market Cap
$16.12B
Enterprise Value$14.42B
Total Cash (Recent Filing)$790.60M
Total Debt (Recent Filing)$1.05B
Price to Earnings (P/E)15.9
Beta0.73
Next Earnings
Feb 26, 2025EPS Estimate
6.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)22.77
Shares Outstanding44,644,520
10 Day Avg. Volume431,820
30 Day Avg. Volume360,502
Standard Deviation0.10
R-Squared0.09
Alpha0.02
Financial Highlights & Ratios
PEG Ratio0.61
Price to Book (P/B)N/A
Price to Sales (P/S)5.85
Price to Cash Flow (P/CF)10.70
P/FCF Ratio13.40
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit6.97
Enterprise Value/Ebitda9.56
Forecast
1Y Price Target
$387.40Price Target Upside21.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
United Therapeutics News
PremiumCompany Announcements
United Therapeutics Corp. Reports Record Revenue and Growth---
Bulls Say, Bears Say
Bulls Say
New Market OpportunitiesThe IPF and PPF populations present significant opportunities for Tyvaso, with a large addressable market.
Product GrowthRecord patient shipments for combined Tyvaso and Tyvaso DPI despite challenges highlight strong growth potential.
Bears Say
Competitive PressureTyvaso faces growth deceleration due to competition from Liquidia's Yutrepia, impacting sales expectations.
Financial PerformanceMissed consensus for Tyvaso's revenue, which was 7% below expectations, contributed to negative stock reaction.
Pipeline And InnovationLimited conviction on pipeline products and no meaningful updates contribute to uncertainty about future growth.
---
Ownership Overview
7.08% Insiders
25.89% Mutual Funds
0.54% Other Institutional Investors
38.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UTHR FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $221.53 and its highest was $417.81 in the past 12 months.
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $16.12B.
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Feb 26, 2025 which is 5 days ago.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Feb 26, 2025. The company reported $6.19 earnings per share for the quarter, missing the consensus estimate of $6.4 by -$0.21.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is 6.4.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 44,644,520 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $6.19 in its last earnings report, missing expectations of $6.4. Following the earnings report the stock price went down -10.8%.
Which hedge fund is a major shareholder of United Therapeutics?
Currently, no hedge funds are holding shares in UTHR
---
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$387.40 (21.04% Upside)
$387.40 (21.04% Upside)
Blogger Sentiment
Bullish
UTHR Sentiment 88%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 39.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.6%
Last 30 Days ▲ 4.5%
Last 30 Days ▲ 4.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.81%
12-Months-Change
Fundamentals
Return on Equity
19.23%
Trailing 12-Months
Asset Growth
3.18%
Trailing 12-Months
Company Description
United Therapeutics
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. It markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. The firm also involves in the research and development of new indications and delivery devices for its product, and for the organ transplantation-related technologies. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.
---
UTHR Company Deck
---
UTHR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted United Therapeutics' record-breaking revenue and strong growth across major product lines. The company is progressing well with its innovative clinical trials and strategic capital allocation, despite a slight sequential decline in net revenue for Q4 due to contracting adjustments. The sentiment is largely positive, focusing on future growth and advancements.Read More>---
UTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
---
UTHR Stock 12 Month Forecast
Average Price Target
$387.40
▲(21.04% Upside)
Technical Analysis
Best Analysts Covering UTHR
1 Year
1 Year Success Rate
11/16 ratings generated profit
1 Year Average Return
+19.03%
reiterated a buy rating 4 months ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +19.03% per trade.
---